Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GAIN THERAPEUTICS INC (GANX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.96-13.48%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GANX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Limit net losses during clinical investment | The company aims to advance clinical programs despite ongoing losses. | Broken | Net loss worsens beyond -$5.6M per quarter | Net income: $-4.676M FY2026-Q2; GAAP. Published target: Net loss no worse than -$5.6M per quarter. Target period is not explicitly aligned with this observation. Aug 11, 2026-4,675,571 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year view is on watch: recent performance has lagged its industry cohort, while pipeline work is progressing but remains mixed.
The available valuation model has low confidence and points to a 27.69% premium versus peers, with expectations only slightly above the model baseline. The premium appears tied to pipeline optionality, meaning future potential is part of the valuation despite current losses.
Near term, results and execution remain hard to assess because GANX is loss-making and management is rated volatile. Management reports FDA clearance for rexaceract and plans Phase 2 work, while Phase 1b analysis and GT-04686 progress remain expected; recent CEO and president transitions and filed litigation add uncertainty.
The multi-year thesis hinges on delivery of the planned Phase 2 study, final Phase 1b data, and progress toward IND-enabling work for GT-04686. Near term, guidance changes and weaker employment data could weigh on sentiment toward cyclical and Healthcare names, while strength among sector bellwethers could support the sector backdrop.
GANX offers pipeline optionality, but losses, leadership changes, litigation, and mixed execution keep the long-term thesis uncertain. The next clinical milestones and management's ability to deliver on stated plans are central to the 1-3 year view. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.” ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.”
Manage operating expenses amid clinical development | Management is focused on financial discipline amid development. | Broken | Operating loss worsens beyond -$5.4M per quarter | Operating income: $-4.682M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$5.4M in 2026-Q1 equivalent quarters going forward. Target period is not explicitly aligned with this observation. Aug 11, 2026-4,681,652 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.” ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.” Delivery assessment Nov 4, 2026 |
Advance Phase 2 study following FDA IND clearance | Gain Therapeutics has FDA clearance to start Phase 2 trials in Q3 2026. | Intact | Phase 2 study initiation delayed beyond Q3 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.” ““The encouraging biomarker and clinical data generated to date continue to support the potential disease-modifying properties of rexaceract , and we were pleased to further share these findings with the scientific community at the 3rd International GBA1 Meeting.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.74 → $-0.65 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.74 | $225,000 | 3 / 5 |
| 2026-07-25 | $-0.74 | $225,000 | 3 / 5 |
| 2026-07-26 | $-0.74 | $225,000 | 3 / 5 |
| 2026-07-27 | $-0.74 | $225,000 | 3 / 5 |
| 2026-07-28 | $-0.60 | $0 | 3 / 5 |
| 2026-07-29 | $-0.74 | $225,000 | 3 / 5 |
| 2026-07-30 | $-0.60 | $0 | 3 / 5 |
| 2026-07-31 | $-0.60 | $0 | 3 / 5 |
| 2026-08-01 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-02 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-03 | $-0.60 | $0 | 3 / 5 |
| 2026-08-04 | $-0.60 | $0 | 3 / 5 |
| 2026-08-05 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-06 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-07 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-08 | $-0.60 | $0 | 3 / 5 |
| 2026-08-09 | $-0.60 | $0 | 3 / 5 |
| 2026-08-10 | $-0.60 | $0 | 3 / 5 |
| 2026-08-12 | $-0.60 | $0 | 3 / 5 |
| 2026-08-13 | $-0.60 | $0 | 3 / 5 |
| 2026-08-14 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-15 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-16 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-17 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-18 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-19 | $-0.74 | $225,000 | 3 / 5 |
| 2026-08-20 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-21 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-22 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-23 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-24 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-25 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-26 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-27 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-28 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-29 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-30 | $-0.65 | $225,000 | 3 / 5 |
| 2026-08-31 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-01 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-02 | $-0.65 | $225,000 | 3 / 4 |
| 2026-09-03 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-04 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-05 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-06 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-07 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-08 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-09 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-10 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-11 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-12 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-13 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-14 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-15 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-16 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-17 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-18 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-19 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-20 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-21 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-22 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-23 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-24 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-25 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-26 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-27 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-28 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-29 | $-0.65 | $225,000 | 3 / 5 |
| 2026-09-30 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-01 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-02 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-03 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-04 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-05 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-06 | $-0.65 | $225,000 | 3 / 5 |
| 2026-10-07 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-08 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-09 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-10 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-11 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-12 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-13 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-14 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-15 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-16 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-17 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-18 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-19 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-20 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-21 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-22 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-23 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-24 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-25 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-26 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-27 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-28 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-29 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-30 | $-0.65 | $225,000 | 4 / 5 |
| 2026-10-31 | $-0.65 | $225,000 | 4 / 5 |
| 2026-11-01 | $-0.65 | $225,000 | 4 / 5 |
| 2026-11-02 | $-0.65 | $225,000 | 4 / 5 |
| 2026-11-03 | $-0.65 | $225,000 | 4 / 5 |
| 2026-11-04 | $-0.65 | $225,000 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.